GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Debt-to-Equity

ME Therapeutics Holding (XCNQ:METX) Debt-to-Equity : 0.00 (As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Debt-to-Equity?

ME Therapeutics Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.00 Mil. ME Therapeutics Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.00 Mil. ME Therapeutics Holding's Total Stockholders Equity for the quarter that ended in Feb. 2024 was C$1.36 Mil. ME Therapeutics Holding's debt to equity for the quarter that ended in Feb. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ME Therapeutics Holding's Debt-to-Equity or its related term are showing as below:

XCNQ:METX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.47   Med: 0.08   Max: 0.11
Current: 0.03

During the past 2 years, the highest Debt-to-Equity Ratio of ME Therapeutics Holding was 0.11. The lowest was -1.47. And the median was 0.08.

XCNQ:METX's Debt-to-Equity is ranked better than
81.96% of 1081 companies
in the Biotechnology industry
Industry Median: 0.15 vs XCNQ:METX: 0.03

ME Therapeutics Holding Debt-to-Equity Historical Data

The historical data trend for ME Therapeutics Holding's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Debt-to-Equity Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Debt-to-Equity
-1.47 0.08

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Debt-to-Equity Get a 7-Day Free Trial 0.11 0.08 0.08 0.10 -

Competitive Comparison of ME Therapeutics Holding's Debt-to-Equity

For the Biotechnology subindustry, ME Therapeutics Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Debt-to-Equity falls into.


ME Therapeutics Holding Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ME Therapeutics Holding's Debt to Equity Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.04 + 0) / 0.523
=0.08

ME Therapeutics Holding's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.364
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding  (XCNQ:METX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ME Therapeutics Holding Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Debt-to-Equity
Comparable Companies
Traded in Other Exchanges
Q9T:Germany
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
Website
https://www.metherapeutics.com
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines